John Sourbeer
Stock Analyst at UBS
(0.75)
# 3,872
Out of 4,944 analysts
39
Total ratings
36.84%
Success rate
-19.56%
Average return
Main Sectors:
Stocks Rated by John Sourbeer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QGEN Qiagen | Maintains: Neutral | $48 → $50 | $48.97 | +2.10% | 5 | Aug 7, 2025 | |
| WST West Pharmaceutical Services | Maintains: Buy | $285 → $320 | $239.90 | +33.39% | 4 | Jul 25, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Buy | $170 → $240 | $169.08 | +41.94% | 2 | Jul 25, 2025 | |
| CYRX Cryoport | Maintains: Buy | $10 → $11 | $8.49 | +29.56% | 6 | Apr 1, 2025 | |
| STVN Stevanato Group | Maintains: Neutral | $24 → $24 | $21.83 | +7.65% | 2 | Mar 7, 2025 | |
| QDEL QuidelOrtho | Maintains: Neutral | $43 → $45 | $25.19 | +78.64% | 4 | Feb 13, 2025 | |
| PACB Pacific Biosciences of California | Downgrades: Neutral | $2 | $1.21 | +65.29% | 3 | Nov 11, 2024 | |
| ILMN Illumina | Maintains: Neutral | $133 → $145 | $97.38 | +48.90% | 3 | Nov 5, 2024 | |
| MEDP Medpace Holdings | Maintains: Buy | $452 → $480 | $459.29 | +4.51% | 4 | Mar 8, 2024 | |
| BRKR Bruker | Maintains: Buy | $94 → $102 | $32.36 | +215.20% | 3 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $50 | $12.81 | +290.32% | 1 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $142 → $128 | $131.02 | -2.30% | 2 | Jul 27, 2022 |
Qiagen
Aug 7, 2025
Maintains: Neutral
Price Target: $48 → $50
Current: $48.97
Upside: +2.10%
West Pharmaceutical Services
Jul 25, 2025
Maintains: Buy
Price Target: $285 → $320
Current: $239.90
Upside: +33.39%
ICON Public Limited Company
Jul 25, 2025
Maintains: Buy
Price Target: $170 → $240
Current: $169.08
Upside: +41.94%
Cryoport
Apr 1, 2025
Maintains: Buy
Price Target: $10 → $11
Current: $8.49
Upside: +29.56%
Stevanato Group
Mar 7, 2025
Maintains: Neutral
Price Target: $24 → $24
Current: $21.83
Upside: +7.65%
QuidelOrtho
Feb 13, 2025
Maintains: Neutral
Price Target: $43 → $45
Current: $25.19
Upside: +78.64%
Pacific Biosciences of California
Nov 11, 2024
Downgrades: Neutral
Price Target: $2
Current: $1.21
Upside: +65.29%
Illumina
Nov 5, 2024
Maintains: Neutral
Price Target: $133 → $145
Current: $97.38
Upside: +48.90%
Medpace Holdings
Mar 8, 2024
Maintains: Buy
Price Target: $452 → $480
Current: $459.29
Upside: +4.51%
Bruker
Mar 1, 2024
Maintains: Buy
Price Target: $94 → $102
Current: $32.36
Upside: +215.20%
Feb 2, 2023
Initiates: Neutral
Price Target: $50
Current: $12.81
Upside: +290.32%
Jul 27, 2022
Maintains: Buy
Price Target: $142 → $128
Current: $131.02
Upside: -2.30%